Iovance Biotherapeutics Inc (IOVA) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Iovance Biotherapeutics inc   (NASDAQ: IOVA)

Iovance Biotherapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Iovance Biotherapeutics Inc in the second quarter 2026?
Iovance Biotherapeutics Inc recorded a cumulative net loss of $-290 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -40.51%.

Within the Biotechnology & Pharmaceuticals industry 40 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3160 to 3232.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 5.38 % -6.01 % -1.66 % -9.2 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -290 -354 -391 -398 -390
Return On Equity (TTM) -40.51 % -50.17 % -54.54 % -55.25 % -52.87 %
IOVA's Total Ranking # 3232 # 3160 # 2740 # 2743 # 2057
Equity (TTM) in Millions 736 722 699 702 698
Seq. Equity Change 1.98 % 3.32 % -0.53 % 0.54 % -9.04 %
Seq. Net Income Change - - - - -

Back to IOVA Management Effectiveness >> IOVA's 5 Years Annual ROE >> Compare IOVA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 41
Sector # 365
Overall # 3232

Return On Equity Statistics
High Average Low
-25.27 %
-63.88 %
-375.92 %
(Dec 31 2015)   (Mar 31 2014)



  News about Iovance Biotherapeutics inc Return on Equity ROE

Iovance Biotherapeutics Executes Inducement Grants for Key Executives and Staff to Enhance Innovation Amidst Financial Challenges,

In an effort to bolster innovation and maintain a competitive edge within the biotechnology sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has announced a series of inducement stock grants aimed at attracting and retaining talent in a challenging market environment. Notably, the company recently approved stock options and restricted stock units for the new Chief Commercial Officer, Daniel Kirby, as well as a larger initiative to benefit non-executive employees.On February 10, 2025, Iovance granted inducement stock options and restricted stock units totaling an aggregate of 305,000 shares to Daniel Kirby. This announcement highlights Iovance s commitment to empower its leadership team as the company navigates a difficult financial landscape, having reported a cumulative net loss of $410 million for the 12 months ending in the third quarter of 2024. This financial picture is compounded by a negative return on equity (ROE) of -58.43%, which places Iovance well below many of its industry peers—out of 60 companies in the Biotechnology and Pharmaceuticals sector, Iovance s ROE ranks low, although it has improved slightly, ascending from a rank of 3203 in the second quarter of 2024 to 3054 in recent assessments.



IOVA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 699 710 585 500 622
Y / Y Equity Change -1.66 % 21.52 % 17.01 % -19.63 % -5.31 %
Net Income in Millions -391 -372 -444 -396 -342
Y / Y Net Income Change - - - - -
Return On Equity -55.97 % -52.39 % -75.95 % -79.24 % -55.05 %

Back to IOVA Management Effectiveness >> IOVA's 5 Years Annual ROE >> Compare IOVA ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IOVA's' Return on Equity at Yahoo Finance
IOVA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IOVA's Competitors
Subscribers only: Roe for Iovance Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Equity for IOVA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:11:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.